Immunome, Inc.

Immunome, Inc.

IMNMยทNASDAQ

$19.81

-4.7%
HealthcareBiotechnology

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$1.89B
EPS-2.4300
P/E Ratio-8.15
Earnings Date08/05/2026

No Dividend Yield Data

IMNM has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

IMNM has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

IMNM has not reported any net dividends paid values in the available annual periods.

Immunome, Inc.

Immunome, Inc. Dividend History

IMNM ยท NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

IMNM Dividend Payment History

IMNM ยท NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
imnm

Immunome, Inc. Payout Ratio Analysis

IMNM ยท NASDAQ
Dividends Paid
0.00
2025
Net Income
-212.39M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.